Parkinson's disease
Conditions
Interventions
Observation group:None
Sponsors
Peking University Shenzhen Hospital
Eligibility
Sex/Gender
All
Age
45 Years to 95 Years
Inclusion criteria
Inclusion criteria: 1. Research participants voluntarily participate in this trial and sign an informed consent form; 2. Age >= 45 years and <= 95 years (as of the date of signing the informed consent form), gender unrestricted; 3. Patients with PD who meet the diagnostic criteria for PD in our country; 4. Expected survival time of more than 12 months; 5. Willing and able to comply with diagnostic plans, clinical laboratory tests, and other trial procedures.
Exclusion criteria
Exclusion criteria: 1. Presence of tumor or significant cerebrovascular lesions; neurosurgical or other neurological diseases, including epilepsy, encephalitis, or stroke; clinically relevant psychiatric disorders; current or recent history of drug or alcohol abuse/dependence; 2. Exclusion of metabolic, immune, severe heart, liver, lung, kidney diseases, or any type of tumor; 3. Previous use of radioactive nuclides with a time interval of less than 10 physical half-lives from the administration of this study; 4. Currently participating in or planning to participate in any drug or device clinical trial during the study; 5. Known allergy to the injection solution or its excipients; 6. Unable to lie flat or remain still during PET scanning, or intolerance to PET scanning; 7. Presence of abnormalities in the physical examination, ECG, EEG, and clinical laboratory tests during the screening period, as determined by the investigator, which may affect safety or compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Striatal mean SUV to occipital lobe SUV ratio (mcSUVR); | — |
Countries
China
Contacts
Public ContactYang Hongjie
Peking University Shenzhen Hospital
Outcome results
None listed